Skip to main content

Table 3 Regression analysis for primary and secondary outcomes from symptom day 15 onwards

From: Elevated free interleukin-18 associated with severity and mortality in prospective cohort study of 206 hospitalised COVID-19 patients

Outcome Kd = 0.05 nM

Highest free IL-18 response coefficient (standard error)

Odds ratio per 50 pg/ml increase in highest free IL-18 (95% confidence interval)

Significance

Primary outcome

 PaO2/FiO2 Ratio (mmHg)

– 0.377 (0.111)

 

p < 0.03

Secondary outcomes

 Mortality

  Death at 60 days from symptom onset (crude mortality)

 

1.41 (1.1–2.0)

p < 0.03

  Death at 60 days from symptom onset (hypoxaemic respiratory failure)

 

1.90 (1.3–3.1)

p < 0.01

 Organ-support dependency

  Any organ support

 

1.66 (1.1–2.9)

p < 0.05

  Artificial mechanical ventilation only

 

1.66 (1.00–2.9)

p = 0.05

  Per additional organ supported

50.72 (23.0)

 

p < 0.05

  Per additional organ supported (hypoxaemic respiratory failure)✦✸

63.67 (23.3)

 

p < 0.01

 Biochemical inflammatory markers

  C-reactive protein (CRP)

0.065 (0.29)

 

p > 0.5

  Lymphocyte (as % of white blood cells)

− 118.4 (109)

 

p > 0.2

  Neutrophil/lymphocyte ratio

2.67 (1.3)

 

p = 0.05

  Neutrophil/lymphocyte ratio (hypoxaemic respiratory failure)

3.54 (1.4)

 

p < 0.03

  1. Results that reach the significance threshold are bolded
  2. The “hypoxaemic respiratory failure group” excludes 4 patients whose calculated PaO2/FiO2 ratio from values recorded in the last 24 h of life did not fall below 300 mmHg at any time. The group is used to exclude those who died from causes other than hypoxaemic respiratory failure
  3. “Per Additional Organ supported” refers to each new organ supported, out of: vasopressor support; artificial mechanical ventilation; renal replacement therapy